When is GT20029 going to come out?
    9/12/2024

    From the encyclopedia
    Finasteride →

    Frontline, gold standard treatment for combatting androgenic alopecia

    Minoxidil →

    An essential vasodilator with some anti-androgenic effects

    At a glance
    In this question or advice post, the primary subjects mentioned are
    💊 Finasteride (oral)
    💧 Minoxidil (topical)
    the tone is hopeful with some growth results.

    Other terms

    The conversation discusses the anticipation and skepticism around the release of GT20029 for hair loss treatment. The original poster has been using Finasteride and Minoxidil but is hopeful for GT20029, while others express doubts about its timely release and suggest alternatives like KX826 and hair transplants.
    View this post in the Community →

    Similar Community Posts Join

    5 / 5 results

      community When is the cure gonna drop , how much more time

      in Research/Science  112 upvotes 6 months ago
      There is no imminent cure for hair loss, but treatments like Minoxidil, Finasteride, and new drugs such as KX-826, GT-20029, and PP405 are being explored. Current solutions focus on slowing hair loss and stimulating growth, with hopes for better options in the future.

      community PP405 mechanism question - looking for discussion

       7 upvotes 5 months ago
      PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.

      community Won’t pp405 and gt20029 be patented and be almost unreasonably expensive

       29 upvotes 1 year ago
      Concerns about the potential high cost of new hair loss treatments, pp405 and gt20029, were discussed, with some users willing to pay a premium if they are effective. Alternatives like finasteride and minoxidil are mentioned as current, more affordable options, and there is speculation about future generic versions and black market availability.

    Related Research

    6 / 6 results
      The 100 Most Cited Articles in Androgenetic Alopecia: A Bibliometric Analysis

      research The 100 most cited articles in androgenetic alopecia: A bibliometric analysis

      March 2025 in “Medicine”
      This study performed a bibliometric analysis of the 100 most cited articles on androgenetic alopecia from 1975 to 2024, revealing that U.S. authors contributed most and highlighting a trend toward research focused on treatment options, especially between 2020 and 2024.
      Recent Advances in Drug Development for Hair Loss

      research Recent Advances in Drug Development for Hair Loss

      April 2025 in “International Journal of Molecular Sciences”
      This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.
      New Therapeutics in the Management of Androgenetic Alopecia

      research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique

      March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)”
      This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
      Updates in Treatment for Androgenetic Alopecia

      research Updates in Treatment for Androgenetic Alopecia

      January 2025 in “Annals of Dermatology”
      This review discusses current and emerging treatments for androgenetic alopecia, covering mechanisms, efficacy, and safety of both androgen-targeted and non-androgen-targeted approaches, but reports no new clinical results.